Antibody drug conjugate (ADC)

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #ProBio #Therapeutic Antibodies

ProBio and AbTis partner on next-generation antibody-drug conjugate

CRDMO ProBio and South Korean biotechnology company AbTis have agreed an exclusive global licensing agreement for the development of antibody-drug conjugates (ADCs).  AbTis will receive exclusive global rights to develop and commercialise a discovery-stage therapeutic antibody asset generated through ProBio's biologics discovery and development capabilities against an oncology target.  Building… Read More

#Business & Investment #News

Business deal agreement
#Antibody drug conjugate (ADC) #Boehringer Ingelheim #China #Collaboration #Oncology

Boehringer Ingelheim puts China strategy into action with SBP deal

Boehringer Ingelheim and China’s SBP Group have entered a strategic multi-programme agreement with to advance potential cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.   Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s platforms and early-development capabilities with Boehringer Ingelheim’s… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Biotech #Investment #Oncology #Women in STEM

Women in biopharma: Valerie Vanhooren, Ona Therapeutics 

In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Valerie Vanhooren, Co-Founder & CEO, at Ona Therapeutics, about approaches in oncology, the remaining potential in the ADC field, and the advice Valerie… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Ona Therapeutics #Oncology #Phase I trial

Ona Therapeutics moves to Phase I with ADC for advanced cancers

Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers.   The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to… Read More

#Cancer Research #News

Antibody-drug conjugate
#ADC #Antibodies #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Gilead Sciences #Nucleai #Oncology

Nucleai and Gilead Sciences enter oncology ADC collaboration

Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Lonza

Lonza and InduPro to collaborate on next-gen ADC therapies 

Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies.  Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology antigens, supporting the… Read More

#Business & Investment #Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Investment #Life sciences #Oncology

Bead BioPharma emerges from stealth with novel drug platform 

Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform.  The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology.  Bead BioPharma is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Investment

Ona raises $86.6m to advance cancer-targeting ADCs 

Ona Therapeutics has announced it has raised $86.6 million to advance its first-in-class antibody-drug conjugates (ADCs) into clinical development.  The biopharmaceutical company raised the money in a Series B financing round, co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys.  Ona says the proceeds… Read More

#Business & Investment #News

Antibody drug conjugates
#Antibody drug conjugate (ADC) #Biologics #Revvity

Preclinical screening platforms for Antibody-Drug Conjugate therapeutics

This advertorial is sponsored by Revvity. Antibody Drug Conjugates (ADCs) represent one of the most rapidly expanding oncology therapeutic categories. Hundreds of candidates are undergoing active clinical development, with about two hundred companies engaged in ADC development1. Recent regulatory adjustments within the pharmaceutical industry in the US have begun to… Read More

#Exclusive Content

Cancer research
#Antibody drug conjugate (ADC) #Cancer research #CAR T-cell therapy #KRAS #Radiopharmaceuticals

New tactics against hard-to-treat cancers

It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics.  New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting in therapies that… Read More

#Cancer Research #Exclusive Content

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Last chance to register: Overcome the challenges of antibody-drug conjugate development

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, on 6 May 2026, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation,… Read More

Webinar date:
Supported by BioDuro
#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Gain insights into ADC biological activity and mechanism-of-action

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, on 6 May 2026, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #CrossBridge Bio #Eli Lilly #Mergers and acquisitions

Antibody-drug conjugate company CrossBridge Bio acquired by Lilly

Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment.  CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology originally created by… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #VALANX Biotech

VALANX sets up SAB to advance ADC therapeutics 

Biotech company VALANX has unveiled its new Scientific Advisory Board as it prepares to advance antibody-drug conjugate (ADC) therapeutics.  John Lambert has been appointed as Chair, with Morris Rosenberg and Peter de Waele serving on the board alongside him.  Lambert is a leading expert in ADC discovery… Read More

#News